IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
Recruitment status was: Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs directly into the tumor after surgery and combining them with radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining surgery, chemotherapy, and radiation therapy in treating patients who have peritoneal cancer.
| Condition | Intervention | Phase |
|---|---|---|
| Malignant Mesothelioma | Biological: recombinant interferon gamma Drug: cisplatin Drug: doxorubicin hydrochloride Drug: gemcitabine hydrochloride Drug: mitomycin C Procedure: conventional surgery Procedure: hyperthermia treatment Radiation: radiation therapy | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma |
| Study Start Date: | May 2001 |
OBJECTIVES:
- Determine the response rate, duration of response, and duration of survival of patients with peritoneal mesothelioma treated with surgery, intraperitoneal chemotherapy, and whole abdominal radiotherapy.
- Determine the toxicity of this regimen in these patients.
OUTLINE: Patients undergo initial surgery, including total omentectomy and excision of gross disease. Approximately 3-4 weeks after surgery, patients receive intraperitoneal (IP) chemotherapy consisting of doxorubicin IP over 2 hours once weekly on weeks 1, 4, 7, and 10 and cisplatin IP and gemcitabine IP once weekly on weeks 2, 5, 8, and 11. Patients also receive interferon gamma IP once weekly on weeks 13-16.
At approximately week 18-20, patients undergo second-look surgery. Patients with no gross disease receive hyperthermia mitomycin IP and cisplatin IP over 90 minutes.
Approximately 2-4 weeks after second-look surgery, patients undergo radiotherapy 5 days a week for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year, every 6 months for 3 years, and then annually for 5 years.
PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Histologically confirmed malignant mesothelioma
- Measurable or evaluable disease
- Ineligible for other high-priority study
- No CNS metastases
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- SWOG 0-2
- Karnofsky 60-100%
Life expectancy:
- More than 2 months
Hematopoietic:
- WBC greater than 3,000/mm3
- Platelet count greater than 100,000/mm3
Hepatic:
- Bilirubin less than 1.5 times normal
Renal:
- Creatinine clearance at least 45 mL/min
- BUN less than 1.5 times normal
- No significant calcium abnormalities
Cardiovascular:
- No symptomatic cardiovascular disease
- No New York Heart Association class II, III, or IV heart disease
- No congestive heart failure
- No angina pectoris
- No cardiac arrhythmia
- No uncontrolled hypertension
Other:
- No significant phosphate, electrolyte, or other metabolic abnormalities (e.g., metabolic acidosis)
- No uncontrolled psychiatric disorder or neurologic disease
- No seizure disorder
- No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or skin cancer
- No other serious medical or psychiatric illness
- No uncontrolled serious infection
- No senility or emotional instability
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No more than 2 prior chemotherapy regimens
- No more than 1 prior intraperitoneal chemotherapy regimen
- More than 6 weeks since prior chemotherapy
- No other concurrent chemotherapy
Endocrine therapy:
- No concurrent hormonal therapy except for nondisease-related conditions (e.g., insulin for diabetes)
- Concurrent steroids for antiemesis, premedication, adrenal failure, or septic shock allowed
Radiotherapy:
- No prior abdominal, pelvic, or lower chest radiotherapy
Surgery:
- Prior surgical resection preceding disease recurrence allowed
- More than 1 week since prior surgery
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00024271
| United States, New York | |
| Herbert Irving Comprehensive Cancer Center at Columbia University | |
| New York, New York, United States, 10032 | |
| Study Chair: | Robert N. Taub, MD, PhD | Herbert Irving Comprehensive Cancer Center |
More Information
| ClinicalTrials.gov Identifier: | NCT00024271 History of Changes |
| Other Study ID Numbers: |
CDR0000068907 CPMC-IRB-13799 NCI-G01-2015 |
| Study First Received: | September 13, 2001 |
| Last Updated: | January 3, 2014 |
Keywords provided by National Cancer Institute (NCI):
|
localized malignant mesothelioma advanced malignant mesothelioma recurrent malignant mesothelioma |
Additional relevant MeSH terms:
|
Mesothelioma Lung Neoplasms Adenoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Mesothelial Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Gemcitabine Interferons Interferon-gamma |
Doxorubicin Mitomycin Liposomal doxorubicin Mitomycins Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antibiotics, Antineoplastic |
ClinicalTrials.gov processed this record on September 21, 2017